Active

Psoriatic Arthritis

Active

Ankylosing Spondylitis

Moderate to Severe

Juvenile Idiopathic Arthritis

Non-Infectious

Intermediate, Posterior and Panuveitis

Active

Psoriatic Arthritis

Moderate to Severe

Hidradenitis Suppurativa

Gastroenterology

Moderate to Severe

Crohn's Disease

Moderate to Severe

Pediatric Crohn's Disease

Moderate to Severe

Ulcerative Colitis

Ophthalmology

Non-Infectious

Intermediate, Posterior and Panuveitis

For moderate to severe rheumatoid arthritis (RA) in adult MTX‑IR patients1

Older woman in a harness, ziplining
The first approved RA therapy to demonstrate superiority in a head-to-head trial vs HUMIRA (adalimumab) + MTX The first approved RA therapy to demonstrate superiority in a head-to-head trial vs HUMIRA (adalimumab) + MTX The first approved RA therapy to demonstrate superiority in a head-to-head trial vs HUMIRA (adalimumab) + MTX

In SELECT‑COMPARE, RINVOQ + MTX achieved superiority in its ranked secondary endpoints (ACR50, HAQ-DI, and pain reduction) at Week 12.2

ACR=American College of Rheumatology; HAQ-DI=health assessment questionnaire disability index; IR=intolerance or inadequate response; MTX = methotrexate

Clinical Trial Overview

SELECT-COMPARE: Primary endpoint was ACR20 response at Week 12 MTX-IR

*P≤0.001 RINVOQ vs Placebo

SELECT‑COMPARE (Study RA-IV) Study Design Intro:1,2 
48‑week, randomized, double‑blind, active comparator‑controlled study of 1629 adult patients with moderate to severe RA who had an inadequate response to MTX. The primary endpoint was ACR20 response at Week 12 vs Placebo. Prespecified blinded rescue protocol occurred at weeks 14, 18, 22, or 26.

Demonstrated superiority in ACR50 at week 12: RINVOQ + MTX vs HUMIRA (adalimumab) + MTX Demonstrated superiority in ACR50 at week 12: RINVOQ + MTX vs HUMIRA (adalimumab) + MTX Demonstrated superiority in ACR50 at week 12: RINVOQ + MTX vs HUMIRA (adalimumab) + MTX

SELECT-COMPARE:
Superiority Data

SELECT-COMPARE:
Superiority Data

15
29
45*†
-0.3
-0.5
-0.6§
-16
-26
-32∣∣
SELECT-COMPARE: ACR50, HAQ-DI, and PAIN SELECT-COMPARE: ACR50, HAQ-DI, and PAIN SELECT-COMPARE: ACR50, HAQ-DI, and PAIN

P≤0.001 for RINVOQ + MTX vs Placebo + MTX; Analyses were not controlled for multiplicity; P‑values obtained through nominal statistical testing.

Please see HUMIRA full Prescribing Information.

Please see HUMIRA full Prescribing Information.

Demonstrated superiority in ACR50 at week 12: RINVOQ + MTX vs HUMIRA (adalimumab) + MTX Demonstrated superiority in ACR50 at week 12: RINVOQ + MTX vs HUMIRA (adalimumab) + MTX Demonstrated superiority in ACR50 at week 12: RINVOQ + MTX vs HUMIRA (adalimumab) + MTX

SELECT-COMPARE:
ACR502-4

SELECT-COMPARE:
ACR502-4

SELECT-COMPARE: ACR50 SELECT-COMPARE: ACR50 SELECT-COMPARE: ACR50

Treatment groups are by initial randomization. Observations after rescue were handled using NRI (weeks 14-22) and LOCF (week 26).5    

SELECT-COMPARE: Chart legend

P≤0.001 for RINVOQ + MTX vs Placebo + MTX; Analysis was not controlled for multiplicity; P-value obtained through nominal statistical testing.

Please see HUMIRA full Prescribing Information.

Please see HUMIRA full Prescribing Information.

SELECT‑COMPARE

Watch as Dr. Roy Fleischmann discusses RINVOQ efficacy and safety information from the SELECT‑COMPARE study.

SELECT-COMPARE Study Design

Video 1/4

Background information on the robust Phase 3 clinical trial program for RINVOQ and study details for SELECT‑COMPARE.

SELECT-COMPARE Results

Video 2/4

A look at the results of the SELECT‑COMPARE study.

SELECT-COMPARE Safety Data

Video 3/4

An overview of the SELECT‑COMPARE study safety data.

SELECT-COMPARE Highlights

Video 4/4

A summary of the SELECT‑COMPARE trial and important safety information.

Demonstrated superiority in HAQ-DI at week 12: RINVOQ + MTX vs HUMIRA (adalimumab) + MTX Demonstrated superiority in HAQ-DI at week 12: RINVOQ + MTX vs HUMIRA (adalimumab) + MTX Demonstrated superiority in HAQ-DI at week 12: RINVOQ + MTX vs HUMIRA (adalimumab) + MTX

SELECT-COMPARE:
HAQ-DI2,3,5,6

SELECT-COMPARE:
HAQ-DI2,3,5,6

SELECT-COMPARE: HAQ-DI SELECT-COMPARE: HAQ-DI SELECT-COMPARE: HAQ-DI

Treatment groups are by initial randomization (ANCOVA). Observations after rescue treatment switch were imputed as LOCF (weeks 14-26).5

SELECT-COMPARE: Chart legend SELECT-COMPARE: Chart legend SELECT-COMPARE: Chart legend

Please see HUMIRA full Prescribing Information.

Please see HUMIRA full Prescribing Information.

Demonstrated superiority in pain reduction at week 12: RINVOQ + MTX vs HUMIRA (adalimumab) + MTX Demonstrated superiority in pain reduction at week 12: RINVOQ + MTX vs HUMIRA (adalimumab) + MTX Demonstrated superiority in pain reduction at week 12: RINVOQ + MTX vs HUMIRA (adalimumab) + MTX

SELECT-COMPARE:
Pain Reduction2,3,5,7

SELECT-COMPARE:
Pain Reduction2,3,5,7

SELECT-COMPARE: Pain Reduction SELECT-COMPARE: Pain Reduction SELECT-COMPARE: Pain Reduction

Treatment groups are by initial randomization (ANCOVA). Observations after rescue treatment switch were imputed as LOCF (weeks 14-26).5

SELECT-COMPARE: Chart legend

P≤0.001 RINVOQ + MTX vs Placebo + MTX; Analysis was not controlled for multiplicity; P-value obtained through nominal statistical testing.

Please see HUMIRA full Prescribing Information.

Please see HUMIRA full Prescribing Information.

RINVOQ SAFETY DATA

Review the well-studied safety profile of RINVOQ,
including both short- and long-term analyses

INDICATION1

RINVOQ is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate.

Limitation of Use: Use of RINVOQ in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine, is not recommended.

IMPORTANT SAFETY INFORMATION1

WARNING: SERIOUS INFECTIONS, MALIGNANCY, and THROMBOSIS

SERIOUS INFECTIONS

Patients treated with RINVOQ are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant

IMPORTANT SAFETY INFORMATION1

WARNING: SERIOUS INFECTIONS, MALIGNANCY, and THROMBOSIS

SERIOUS INFECTIONS

Patients treated with RINVOQ are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking

INDICATION1

RINVOQ is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate.

Limitation of Use: Use of RINVOQ in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine, is not recommended.

IMPORTANT SAFETY INFORMATION1

WARNING: SERIOUS INFECTIONS, MALIGNANCY, and THROMBOSIS

SERIOUS INFECTIONS

Patients treated with RINVOQ are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant

IMPORTANT SAFETY INFORMATION1

WARNING: SERIOUS INFECTIONS, MALIGNANCY, and THROMBOSIS

SERIOUS INFECTIONS

Patients treated with RINVOQ are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking